STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #708 by analyst upside · 2026-08-13
AARD
Aardvark Therapeutics, Inc.
Healthcare · Market Cap $144M · P/E 0x
ANALYST PRICE TARGET
+120.7%
implied upside to consensus target
Current Price $6.57
Consensus Target $14.5
Bull Target $45.0
Bear Target $3.0
Analysts Covering 10
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
5
Hold
3
Sell
2
52-Week Low $3.35
52-Week High $17.94
YTD Return -50.2%
FUNDAMENTALS
Market Cap $144M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.21
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.35
52-Week High $17.94
Current Price $6.57
Bear Target $3.0
Bull Target $45.0
● Now $6.57 ● Target $14.5
TRADING DATA
Avg Volume 270K
YTD Return -50.2%
Analyst Count 10
Consensus Hold
Upside to Target +120.7%
Last Updated 2026-08-13

ANALYST SUMMARY

Aardvark Therapeutics, Inc. (AARD) is currently trading at $6.57 with a Wall Street consensus price target of $14.5, implying potential upside of 120.7% over the next 12 months. 10 analysts currently cover AARD, with a consensus rating of Hold - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $45.0, while the most cautious has a target of $3.0.

AARD operates in the Healthcare sector with a market capitalisation of $144M. The stock is down 50.2% year-to-date and is currently trading near the lower end of its 52-week range of $3.35 – $17.94.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AARD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B. Riley Securities - Reiterated
Buy → Buy 2026-05-15 17% win rate (6 calls)
BTIG ↓ Downgrade
Buy → Neutral 2026-05-15 38% win rate (8 calls)
Morgan Stanley ↓ Downgrade
Equal-Weight → Underweight 2026-05-15 Building track record
BTIG reit
Buy → Buy 2026-03-24 38% win rate (8 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-03-02 14% win rate (7 calls)
BTIG - Reiterated
Buy → Buy 2026-03-02 38% win rate (8 calls)
Morgan Stanley ↓ Downgrade
Overweight → Equal-Weight 2026-03-02 Building track record
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-03-02 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
25
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →